Cytokinetics to Present at September Healthcare Conferences
(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/06/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of September:
Rodman & Renshaw 13th Annual Healthcare Conference
Date: Tuesday, September 13, 2011
Time: 8:10 AM Eastern Time
Location: The Waldorf=Astoria Hotel, New York, New York
UBS Global Life Sciences Conference
Date: Tuesday, September 20, 2011
Time: 1:30 PM Eastern Time
Location: The Grand Hyatt Hotel, New York, New York
Sixth Annual JMP Securities Healthcare Conference
Date: Tuesday, September 27, 2011
Time: 1:00 PM Eastern Time
Location: The St. Regis Hotel, New York, New York
Interested parties may access the live audio webcasts of these presentations by visiting the Investor Relations section of the Cytokinetics website at . The webcast replay of these presentations will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of the event.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, , is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which CK-2017357 demonstrated potentially clinically relevant pharmacodynamic effects in a Phase IIa trial. Cytokinetics is also conducting research directed to compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic obstructive pulmonary disorder (COPD). In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at .
Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan
(Investors and Media)
Director, Investor Relations
(650) 624-3000
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2011 - 20:00 Uhr
Sprache: Deutsch
News-ID 63141
Anzahl Zeichen: 0
contact information:
Town:
SOUTH SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Present at September Healthcare Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
